Risiko-stratificeret deeskaleret hormonterapi med strålebehandling til behandling af prostatakræft
Risikostratificeret de-eskaleret de-intensiveret behandling for højrisikoprostatacancerpatienter baseret på patologiske kriterier, genetisk score og biologisk billeddannelse
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Research has shown that long-term ADT is beneficial for patients with high-risk prostate cancer. However, there are few studies that determine ADT treatment based on risk factors. Giving risk based de-escalated ADT with radiation therapy may be as effective as giving more ADT in treating high-risk prostate cancer.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. Recovery of the Expanded Prostate Cancer Index Composite (EPIC) hormonal domain to baseline levels at 2-years.
EXPLORATORY OBJECTIVES:
I. After completion of radiation therapy, determine the incidence of:
Ia. Grade 2 or greater genitourinary (GU) and gastrointestinal (GI) toxicity at 6 months (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0); Ib. Grade 3 or greater GU and GI toxicity at 6 months (CTCAE version 5.0); Ic. Patient-reported quality of life; Id. Impotence after the use of radiation therapy at 3 years; Ie. Freedom from biochemical failure (FFBF) at 5 years; If. Clinical failure: local and/or distant at 5 years; Ig. Salvage androgen deprivation use (SAD) at 5 years; Ih. Progression free survival: using clinical, biochemical and SAD as events at 5 years; Ij. Overall survival at 5 years; Ik. Disease-specific survival at 5 years. II. Determine overall GI and GU toxicity.
OUTLINE: Patients are assigned to 1 of 3 risk groups.
GROUP I (LOW RISK): Patients undergo radiation therapy to the prostate bed over 2 - 6 weeks.
GROUP II (INTERMEDIATE RISK): Patients receive ADT subcutaneously (SC) or intramuscularly (IM) for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to the prostate bed over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy.
GROUP III: (HIGH RISK): Patients receive ADT SC or IM with or without abiraterone acetate for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to identified areas over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy.
Additionally, patients undergo positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI), and blood sample collection throughout the trial.
After completion of study treatment, patients are followed up at months 3 and 12, then yearly for up to year 5 followed by every 2 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forenede Stater, 85259
- Mayo Clinic in Arizona
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically confirmed high risk prostate adenocarcinoma
- Pathologic stages T1c-T4, N0-Nx-N1, M0-1 as staged by the pathology report (AJCC Criteria 8th Edition [Ed].)
- One or more high risk features including Gleason 8-10, T3-T4, prostate specific antigen (PSA) ≥ 20
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Patients must sign institutional review board (IRB) approved study specific informed consent
- Patients must complete all required pre-entry tests
- Patients must be at least 18 years old
- Oligometastatic prostate cancer defined as disease in up to 5 distant or regional areas (group 3 only)
Exclusion Criteria:
- Previous pelvic radiation
- Prior androgen suppression therapy for prostate cancer for more than 6 months
- Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed)
- Prior systemic chemotherapy for prostate cancer
- History of proximal urethral stricture requiring dilatation
- Current and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low-molecular weight heparin, clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or place markers)
- Major medical, addictive or psychiatric illness which in the investigator's opinion, will prevent the consent process, completion of the treatment and/or interfere with follow-up. (Consent by legal authorized representative is not permitted for this study)
- Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed)
- History of myocardial infarction or decompensated congestive heart failure (CHF) within the last 6 months
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group I (radiation therapy)
Patients undergo radiation therapy to the prostate bed over 2 - 6 weeks. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study. |
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo PET
Andre navne:
Undergo radiation therapy
Andre navne:
|
|
Eksperimentel: Group II (ADT, radiation therapy)
Patients receive ADT SC or IM for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to the prostate bed over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study. |
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo PET
Andre navne:
Undergo radiation therapy
Andre navne:
Given SC or IM
Andre navne:
|
|
Eksperimentel: Group III (ADT, radiation therapy, abiraterone acetate)
Patients receive ADT SC or IM with or without abiraterone acetate for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy to identified areas over 2 - 6 weeks starting on week 8-10 of ADT hormone therapy. Additionally, patients undergo PET, CT or MRI and blood sample collection throughout the study. |
Undergo blood sample collection
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Ancillary studies Undergo PET
Andre navne:
Undergo radiation therapy
Andre navne:
Given SC or IM
Andre navne:
Given abiraterone acetate
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Hormonal domain scores
Tidsramme: At baseline and up to 2 years
|
Measured by the Expanded Prostate Cancer Index Composite. Comparison will be made using a one-sided, paired-difference t-test, with a Type I error rate of 0.025. |
At baseline and up to 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Carlos E. Vargas, M.D., Mayo Clinic
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Hypofysehormon-frigivende hormoner
- Hypothalamiske hormoner
- Peptidhormoner
- Neuropeptider
- Peptider
- Aminosyrer, peptider og proteiner
- Oligopeptider
- Nervevævsproteiner
- Proteiner
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Fysiske fænomener
- Polycykliske forbindelser
- Steroider
- SMUSED-RING-forbindelser
- Kemiteknikker, analytisk
- Spektrumanalyse
- Androstenes
- Androstanes
- Abirateronacetat
- Gonadotropin-frigivende hormon
- Strålebehandling
- Stråling
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
Andre undersøgelses-id-numre
- GMROA2256
- GMROA2256 (Anden identifikator: Mayo Clinic in Arizona)
- NCI-2024-03020 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 22-012591 (Anden identifikator: Mayo Clinic Institutional Review Board)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .